Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

Pierre Fabre Laboratories to Acquire from Atara Biotherapeutics Commercialization Rights to EBVALLO® in the United States, Canada and All Remaining Markets Pierre Fabre Laboratories to Take Over All Manufacturing, Clinical, and Regulatory Activities for EBVALLO® Following Transition…